Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 3.02, 9.01 · 8-K

GlucoTrack, Inc.

Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities

Item 1.01. Entry Into a Material Definitive Agreement. On October 13, 2026, Glucotrack, Inc. (the “Company”) entered into a Waiver Agreement (the “Waiver”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued pursuant to the Securities Purchase Agreement, dated as of July 14, 2026, by and among th…

Filed Oct 19, 2026Accepted Oct 19, 2026, 4:05 PM EDTCIK 1506983Accession 0001493152-26-047582
Share

Company context

Inc. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.

Current securities

Historical securities (2)

Recent company filings

  1. NT 10-Q filingNov 17, 2026
  2. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingOct 29, 2026
  3. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other EventsOct 28, 2026
  4. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD DisclosureOct 22, 2026
  5. S-1/A filingOct 14, 2026

Registered securities in this filing

GLUCOTRACK, INC. · 8-K · Filed 2026-10-19

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
GCTK
Exchange
NASDAQ
Classification
COMMON
Filing context

Context: AsOf2026-10-13

Dimensions: Not supplied

Accession 000149315226047582 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 1.01, 3.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01. Entry Into a Material Definitive Agreement. On October 13, 2026, Glucotrack, Inc. (the “Company”) entered into a Waiver Agreement (the “Waiver”) with certain holders (the “Holders”) of warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued pursuant to the Securities Purchase Agreement, dated as of July 14, 2026, by and among the Company and the Holders (such agreement, the “Purchase Agreement,” and such warrants, the “Existing Warrants”). The Waiver was executed by holders constituting the Requisite Holders (as defined in the Purchase Agreement), as required by Section 11.9 of the Purchase Agreement. The Waiver provides for the waiver and termination of (i) the restriction under Section 5.10(a) of the Purchase Agreement on the Company’s issuance of, entry into any agreement to issue, or announcement of the issuance of, shares of Common Stock or Common Stock equivalents (other than exempted securities) until ninety (90) days following the effectiveness of the registration statement and receipt of the stockholder approval contemplated thereby, which waiver is effective as to all Holders, and (ii) the exercise price adjustment under Section 3(e) of the Existing Warrants in connection with any variable rate transaction, which waiver, in accordance with Section 5(m) of the Existing Warrants, is effective only with respect to the Existing Warrants held by Holders that executed the Waiver. In consideration for the Waiver, the Company has become obligated to issue new warrants (the “New Warrants”) to purchase an aggregate of 406,198 shares of Common Stock (the “Warrant Shares”) to the Holders. The New Warrants have an exercise price of $7.50 per share, expire five (5) years from the date of issuance, and are not exercisable unless and until the Company obtains stockholder approval for the issuance of the Warrant Shares in accordance with Nasdaq Listing Rule 5635. Exercise of the New Warrants is subject to a 9.99% beneficial ownership limitation, and the exercise price is subject to customary adjustments, subject to a floor price equal to 20% of the closing sale price of the Common Stock on the date of issuance of the New Warrants. Except as expressly set forth in the Waiver, the Purchase Agreement, the Existing Warrants and the other transaction documents remain in full force and effect. The foregoing descriptions of the Waiver and the New Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Waiver and the form of New Warrant, which are filed as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
Item 3.02Item 3.02 - Unregistered Sales of Equity
Item 3.02. Unregistered Sales of Equity Securities. The disclosure set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 3.02 by reference. The New Warrants and the Warrant Shares will be issued by the Company to the Holders in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) of the Securities Act.
Filed exhibits (1)
EX-4.1 (by filename) ex4-1.htm

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. GLUCOTRACK, INC. WARRANT TO PURCHASE COMMON STOCK Date of Issuance: October [__], 2026 (“ Issuance Date ”) Warrant Shares: [__] Glucotrack, Inc., a Delaware corporation (the “ Company ”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [__], the registered holder hereof or its permitted assigns (the “ Holder ”)…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.